Why the study?
Does circRNA DICAR regulate diabetic cardiomyopathy and cardiomyocyte pyroptosis in preclinical models?
Does circRNA DICAR regulate diabetic cardiomyopathy and cardiomyocyte pyroptosis in preclinical models?
CircRNA DICAR and its synthesized junction part (DICAR-JP) inhibit diabetic cardiomyopathy and cardiomyocyte pyroptosis, presenting a potential novel therapeutic target for DCM.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for DICAR in diabetic cardiomyopathy; leaves open translation to human therapy.
In this study, we identified that a conserved circular RNA (circRNA) DICAR, which was downregulated in diabetic mouse hearts. DICAR had an inhibitory effect on diabetic cardiomyopathy (DCM), as the spontaneous cardiac dysfunction, cardiac cell hypertrophy, and cardiac fibrosis occurred in DICAR deficiency (DICAR+/−) mice, whereas the DCM was alleviated in DICAR-overexpressed DICARTg mice. At the cellular level, we found that overexpression of DICAR inhibited, but knockdown of DICAR enhanced the diabetic cardiomyocyte pyroptosis. At the molecular level, we identified that DICAR-VCP-Med12 degradation could be the underlying molecular mechanism in DICAR-mediated effects. The synthesized DICAR junction part (DICAR-JP) exhibited a similar effect to the entire DICAR. In addition, the expression of DICAR in circulating blood cells and plasma from diabetic patients was lower than that from health controls, which was consistent with the decreased DICAR expression in diabetic hearts. DICAR and the synthesized DICAR-JP may be drug candidates for DCM.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: